BACKGROUND Hypoparathyroidism(HP)is a rare endocrine disorder,while situs inversus totalis(SIT)is a rare condition in which the internal organs are positioned in a mirrored pattern compared to their usual positions.Th...BACKGROUND Hypoparathyroidism(HP)is a rare endocrine disorder,while situs inversus totalis(SIT)is a rare condition in which the internal organs are positioned in a mirrored pattern compared to their usual positions.This case illustrates some potential shared mechanisms between HP and SIT,highlighting the importance of accurate identification and prompt first emergency,offering insights for future research.CASE SUMMARY This report discusses a case of a middle-aged patient with adolescent-onset HP with concurrent SIT.The patient experienced recurrent episodes of increased neuromuscular excitability(manifesting as spasms in the hands and feet and laryngospasms)and even periods of unconsciousness.Initially,these symptoms led to a misdiagnosis of epilepsy.Nevertheless,upon thorough examination and treatment in the general medicine ward,the correct diagnosis was established.Corresponding treatment resulted in improved management of the patient’s symptoms.CONCLUSION Co-occurrence of HP and SIT may be associated with genetic mutations,chromosomal anomalies,or hereditary factors,as may other similar conditions.展开更多
在精确AMS^(14)C测年的基础上,对采自重庆中梁山岩溶洼地的剖面样品进行了孢粉分析,并结合详细的历史文献资料,获取了该地区近700年以来的植被变迁与石漠化演化记录。结果显示:(1)1274—1553 cal a AD研究区周围主要分布以松属、柏科/...在精确AMS^(14)C测年的基础上,对采自重庆中梁山岩溶洼地的剖面样品进行了孢粉分析,并结合详细的历史文献资料,获取了该地区近700年以来的植被变迁与石漠化演化记录。结果显示:(1)1274—1553 cal a AD研究区周围主要分布以松属、柏科/杉科占优势的亚热带常绿针叶林,伴人植物花粉少量出现,人类活动相对较弱。(2)1553—1780 cal a AD,针叶树松属、柏科/杉科花粉含量下降,伴人植物花粉增多,指示研究区人类活动开始加强。(3)1780—1840 cal a AD,松属花粉含量急剧下降,灌木和伴人植物花粉急剧增加,指示该地区人类活动加剧,石漠化现象出现。(4)1840—2000 cal a AD,玉米花粉含量大幅度增加,表明人类活动更加强烈,石漠化现象进一步加剧。近700年来不断增加的人类活动是重庆地区植被退化、石漠化现象严重的重要因素。该研究结果对重庆岩溶地区的全面治理,恢复和重建自然生态环境具有重要的指示意义。展开更多
Objective：To evaluate the efficacy and tolerability of sorafenib combined with cryoablation in treating unresectable hepatocellular carcinoma （HCC）.Methods：Patients with unresectable advanced HCC received cryoabla...Objective：To evaluate the efficacy and tolerability of sorafenib combined with cryoablation in treating unresectable hepatocellular carcinoma （HCC）.Methods：Patients with unresectable advanced HCC received cryoablation and sorafenib at a dose of 400 mg twice daily in 4-week cycles on the same day of the cryoablation.Tumor response,median overall survival and the median time to radiological progression were calculated and the toxicity was evaluated.Results：Seventy-eight patients with unresectable HCC were involved in this study.The median age was 52 years （range,22-81 years）.The Eastern Cooperative Oncology Group （ECOG） performance status scores were 0 （39.7%）,1 （55.1%）,and 2 （5.1%）.Nine （11.5%） patients were at Barcelona clinic liver cancer （BCLC） stage A,twenty-four （30.8%） patients were at stage B and 45 （57.7%） patients were at stage C.Five （6.4%） achieved partial responses,and 34 （43.6%） achieved stable disease.The median time to progression （TTP） for all enrolled patients was 6.6 months and the median overall survival （OS） was 12.2 months.Conclusion：Cryoablation combined with sorafenib demonstrates good efficacy and acceptable tolerability in treating unresectable advanced HCC patients.展开更多
基金Supported by Zunyi Science and Technology Plan Program No.HZ(2022)48Zunyi Science and Technology Plan Program,No.HZ(2023)60.
文摘BACKGROUND Hypoparathyroidism(HP)is a rare endocrine disorder,while situs inversus totalis(SIT)is a rare condition in which the internal organs are positioned in a mirrored pattern compared to their usual positions.This case illustrates some potential shared mechanisms between HP and SIT,highlighting the importance of accurate identification and prompt first emergency,offering insights for future research.CASE SUMMARY This report discusses a case of a middle-aged patient with adolescent-onset HP with concurrent SIT.The patient experienced recurrent episodes of increased neuromuscular excitability(manifesting as spasms in the hands and feet and laryngospasms)and even periods of unconsciousness.Initially,these symptoms led to a misdiagnosis of epilepsy.Nevertheless,upon thorough examination and treatment in the general medicine ward,the correct diagnosis was established.Corresponding treatment resulted in improved management of the patient’s symptoms.CONCLUSION Co-occurrence of HP and SIT may be associated with genetic mutations,chromosomal anomalies,or hereditary factors,as may other similar conditions.
文摘在精确AMS^(14)C测年的基础上,对采自重庆中梁山岩溶洼地的剖面样品进行了孢粉分析,并结合详细的历史文献资料,获取了该地区近700年以来的植被变迁与石漠化演化记录。结果显示:(1)1274—1553 cal a AD研究区周围主要分布以松属、柏科/杉科占优势的亚热带常绿针叶林,伴人植物花粉少量出现,人类活动相对较弱。(2)1553—1780 cal a AD,针叶树松属、柏科/杉科花粉含量下降,伴人植物花粉增多,指示研究区人类活动开始加强。(3)1780—1840 cal a AD,松属花粉含量急剧下降,灌木和伴人植物花粉急剧增加,指示该地区人类活动加剧,石漠化现象出现。(4)1840—2000 cal a AD,玉米花粉含量大幅度增加,表明人类活动更加强烈,石漠化现象进一步加剧。近700年来不断增加的人类活动是重庆地区植被退化、石漠化现象严重的重要因素。该研究结果对重庆岩溶地区的全面治理,恢复和重建自然生态环境具有重要的指示意义。
文摘Objective：To evaluate the efficacy and tolerability of sorafenib combined with cryoablation in treating unresectable hepatocellular carcinoma （HCC）.Methods：Patients with unresectable advanced HCC received cryoablation and sorafenib at a dose of 400 mg twice daily in 4-week cycles on the same day of the cryoablation.Tumor response,median overall survival and the median time to radiological progression were calculated and the toxicity was evaluated.Results：Seventy-eight patients with unresectable HCC were involved in this study.The median age was 52 years （range,22-81 years）.The Eastern Cooperative Oncology Group （ECOG） performance status scores were 0 （39.7%）,1 （55.1%）,and 2 （5.1%）.Nine （11.5%） patients were at Barcelona clinic liver cancer （BCLC） stage A,twenty-four （30.8%） patients were at stage B and 45 （57.7%） patients were at stage C.Five （6.4%） achieved partial responses,and 34 （43.6%） achieved stable disease.The median time to progression （TTP） for all enrolled patients was 6.6 months and the median overall survival （OS） was 12.2 months.Conclusion：Cryoablation combined with sorafenib demonstrates good efficacy and acceptable tolerability in treating unresectable advanced HCC patients.
